NTRA News and Press, Natera Inc. From 10/08/20

Natera's Panorama® NIPT Receives Average Risk Coverage for an Additional 24 Million Lives Fourth largest health plan adopts average risk coverage post-ACOG and SMFM guideline change PR Newswire SAN CARLOS, Calif., Oct. 8, 2020 SAN CARLOS, Calif. , Oct....

Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge Celebrities and the public are making creative golf trick shot videos to create awareness and encourage donations for kidney disease patients PR Newswire SAN CARLOS, ...

Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case Upholds validity of Natera's patents; patent case against ArcherDX continues PR Newswire SAN CARLOS, Calif., Oct. 5, 2020 SAN CARLOS, Calif. , Oct. 5, 2020 /PRNewswire/ -- Nat...

Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™ PR Newswire SAN CARLOS, Calif., Oct. 2, 2020 SAN CARLOS, Calif. , Oct. 2, 2020 /PRNewswire/ -- Nate...

Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monito...

SAN CARLOS, Calif. , Sept. 18, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society fo...

In preparing this research, we ran detailed financial statement analysis against the portfolios of the thirteen small cap growth fund investment managers with the best ten-year performance according to CityWire. Those funds, in order of performance, starting with the best first: Virtus...

SAN CARLOS, Calif. , Sept. 14, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, announced an expansive program to improve care for organ transplant patients with a history of cancer, using the Signatera™ test for molecula...

SAN CARLOS, Calif. , Sept. 11, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative Contractor (MAC) for Northern California , has finalized a final local coverage artic...

Natera  (NASDAQ: NTRA ) has priced its public offering of ~4.2M common shares at $60.00/share. More news on: Natera, Inc., Healthcare stocks news, Read more ...